At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 23, 2026 at 09:02 ET
The FDA has approved an IDE supplement expanding Alpha Tau's IMPACT pilot trial for pancreatic cancer to include 10 additional patients receiving gemcitabine/nab-paclitaxel chemotherapy, increasing total enrollment from 30 to 40. The expansion allows evaluation of Alpha DaRT in combination with both major first-line chemotherapies, broadening the potential development path for this investigational therapy in a high-unmet-need population.
- FDA approved an IDE supplement to expand the IMPACT trial from 30 to 40 patients
- Expansion includes 10 new patients receiving gemcitabine/nab-paclitaxel alongside Alpha DaRT
- Trial now covers both major first-line chemotherapies: mFOLFIRINOX and gemcitabine/nab-paclitaxel
- Patient recruitment now expected to complete in Q3 2026, delayed from Q2 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access